Pediatric Obesity Management Market Size to Hit US$ 4.37 Billion by 2031 | Growth Plus Reports
Growth Plus Reports
5 min read
Growth Plus Reports
Newark, New Castle, USA, June 14, 2023 (GLOBE NEWSWIRE) -- The market analysis of the global pediatric obesity management market was conducted by Growth Plus Reports in 2022 and is valued at US$ 3.02 billion. The market is expected to hit a revenue CAGR of 4.2% to reach US$ 4.37 billion by 2031.
Analysis of the global market for pediatric obesity management indicates that during the forecast period, revenue share is likely to increase significantly. Therapeutics for pediatric obesity management include drugs or dietary additions that are used to treat childhood and adolescent obesity.
Key Takeaways:
The increasing number of children with obesity is driving the market revenue share.
The rising risks of diabetes and other cardiovascular disease is driving the market demand.
The demand for precise drug treatment is increasing the market revenue growth rapidly.
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
Recent Development in the Pediatric Obesity Management Market:
In December 2022, Novo Nordisk's semaglutide (Wegovy) was given FDA approval to treat obesity in children patients 12 years of age and older.
In June 2022, For individuals with obesity who are of 12 years or older, the FDA authorized a new indication for phentermine and topiramate extended-release capsules (brand name Qsymia).
Competitive Landscape
A list of the companies operating in the global market for pediatric obesity management includes:
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
AstraZeneca
Herbalife Ltd
Apollo Endosurgery
Market Drivers and Restraints:
The global pediatric obesity management market revenue is driven by the increasing measures to control childhood obesity, the demand for an effective treatment option, and the introduction of novel products in the market for curing pediatric obesity.
However, due to the unawareness of the information and high costs of treatment, the pediatric obesity management market revenue growth is expected to be restrained.
Market Segmentation:
Based on types, the global pediatric obesity management market is segmented into medication and supplements.
The medication segment is further sub-segmented into lipase inhibitors, anorectics, serotonin receptor agonists, incretin mimetics, and melanocortin 4 (MC4) receptor agonists.
Based on distribution channels, the global hospital pharmacies, retail pharmacies, and online pharmacies.
Based on the types, the medication segment dominates the global pediatric obesity management market with the largest revenue share. This sizable share of revenue is attributed to several drugs, including orlistat (Lipase inhibitor), liraglutide (incretin mimetics), and phentermine/topiramate (Anorectics), which are the most common types of treatment options. Furthermore, the global pediatric obesity management market revenue is also accelerated by their effective results as a health supplement and negative side effects.
Regional Growth Dynamics
Based on the region, North America, with the largest revenue share, dominates the global pediatric obesity management market. This large share of revenue is attributed to the sophisticated healthcare infrastructure with substantial public support for healthcare initiatives and expenditures in R&D.
Report Coverage
Global market research on the pediatric obesity management market was done in-depth by Growth Plus Reports. We looked at the core market traits, noteworthy investment prospects, regional growth trends, ten-year revenue projections, rival market participants, and mergers and acquisitions.
Table of Content
INTRODUCTION
Market Ecosystem
Timeline Under Consideration
Historical Years – 2021
Base Year – 2022
Forecast Years – 2023 to 2031
Currency Used in the Report
RESEARCH METHODOLOGY
Research Approach
Data Collection Methodology
Data Sources
Secondary Sources
Primary Sources
Market Estimation Approach
Bottom Up
Top Down
Market Forecasting Model
Limitations and Assumptions
PREMIUM INSIGHTS
Current Market Trends (COVID-19 Perspective)
Key Players & Competitive Positioning (2022)
Regulatory Landscape
Reimbursement Scenario
Epidemiology and Patient Population
MARKET DYNAMICS
Drivers
Restraints/Challenges
Opportunities
GLOBAL PEDIATRIC OBESITY MANAGEMENT MARKET - ANALYSIS & FORECAST, BY TYPE
Medication
Lipase Inhibitors
Anorectics
Serotonin Receptor Agonist
Incretin Mimetics
Melanocortin 4 (MC4) Receptor Agonists
Supplements
GLOBAL PEDIATRIC OBESITY MANAGEMENT MARKET - ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
Anticholesteremic Agents Market by Drug Class (Bile Acid Resins, Statins), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031
Glucose Elevating Agents Market by Products (Glucagon, Diazoxide), Indication (Hypoglycemia, Insulinoma), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), – Global Outlook & Forecast 2023-2031
Expat Health Insurance Market by Service Provider (Private, Public), Indication (Emergency Medical Evacuation, Maternity Coverage, Outpatient Coverage), Term Plan (Short-Term, Long-Term) – Global Outlook & Forecast 2023-2031
Veterinary Euthanasia Drugs Market by Animal Type (Companion Animals and Farm Animals), Route of Administration (Injectable Euthanasia Drugs, Inhalational Euthanasia Drugs) – Global Outlook & Forecast 2023-2031
MISME Syndrome Market by Treatment (Surgery, Radiotherapy, Pharmacotherapy) – Global Outlook & Forecast 2023-2031
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020".
